Metagenomi Therapeutics, Inc. MGX
We are an in vivo genome editing company capitalizing on our proprietary technologies to create curative genetic medicines for patients. We were founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel gene editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. We leverage machine learning and artificial intelligence to enhance our signature gene editing systems. In late 2025, we made the decision to strategically reprioritize our pipeline and discovery efforts to focus our resources on driving forward our lead programs that utilize our most advanced, signature gene-editing capabilities with the highest probability of success while maintaining financial discipline to drive sustainable growth and long-term value. We increased our focus on high-value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways to accelerate programs with the potential to deliver therapeutic benefits of gene editing to patients.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $25.2M | $52.3M | $44.8M | — |
| R&D | $94.4M | $109.2M | $94.4M | — |
| SG&A | $26.8M | $32.0M | $28.8M | — |
| Total operating expenses | $121.2M | $141.2M | $123.2M | — |
| Operating income | -$96.0M | -$88.9M | -$78.5M | — |
| Pre-tax income | -$87.9M | -$83.6M | -$60.2M | — |
| Income tax | $58.0K | $5.5M | $8.0M | — |
| Net income | -$87.9M | -$78.1M | -$68.3M | — |
| EPS, basic | -2.36 | -2.36 | -20.05 | — |
| EPS, diluted | -2.36 | -2.36 | -20.05 | — |
| Shares, diluted (wtd. avg.) | 37.3M | 33.0M | 3.4M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $41.7M | $27.4M | $145.9M | $190.5M |
| Short-term investments | $119.1M | $220.9M | $130.6M | — |
| Receivables | $305.0K | $1.3M | $2.5M | — |
| Total current assets | $165.5M | $258.0M | $278.3M | — |
| Property, plant and equipment | $12.3M | $17.7M | $21.5M | — |
| Total assets | $221.1M | $324.6M | $364.8M | — |
| Accounts payable | $1.5M | $533.0K | $1.8M | — |
| Total current liabilities | $22.9M | $37.3M | $68.9M | — |
| Total liabilities | $62.5M | $89.7M | $149.7M | — |
| Retained earnings | -$310.9M | -$223.0M | -$144.9M | — |
| Total equity | $158.6M | $234.9M | -$135.6M | -$74.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$88.9M | -$109.1M | -$91.4M | — |
| Depreciation and amortisation | $5.3M | $5.4M | $4.2M | — |
| Stock-based compensation | $11.9M | $16.2M | $6.9M | — |
| Capital expenditure | $574.0K | $3.1M | $9.8M | — |
| Investing cash flow | $103.5M | -$88.2M | $45.7M | — |
| Financing cash flow | -$356.0K | $84.0M | $1.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-093976.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $44.8M | $52.3M | $25.2M |
| Gross profit | — | — | — | — |
| Net income | — | -$68.3M | -$78.1M | -$87.9M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |